Aster DM Q4 FY26: Revenue up 18% to ₹1,182 Cr, EBITDA up 31%, merger advances

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF

ASTERDM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.2%1-day move

₹707.00

prior close

₹725.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+2.8+4.0+4.6+2.4+5.2+3.5+5.0+5.0+4.5+4.1+5.0+4.5+11.6—

Up moveDown movePending

AI summary

Aster DM Q4 FY26: Revenue up 18% YoY to ₹1,182 Cr. Operating EBITDA (ex-Kasaragod) rose 31% to ₹253 Cr; margins expanded to 21.7% from 19.3%. Normalised PAT (ex-Kasaragod) up 45% to ₹153 Cr. Proforma combined with QCIL: Revenue ₹2,361 Cr (+18%), EBITDA ₹517 Cr (+25%). Patient volumes grew 15%. Merger with Quality Care India got 96.68% shareholder approval; CCI approval received, NCLT order pending. Expected to close Q1 FY27, creating a 10,623+ bed platform across 28 cities.

Likely market impact

Strong Q4 with double-digit revenue and EBITDA growth, margin expansion, and major merger with QCIL nearing completion — positive for growth and scale.